Compass Therapeutics, Inc. (CMPX) vs Nkarta, Inc. (NKTX)

A side-by-side comparison of Compass Therapeutics, Inc. and Nkarta, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CMPX vs NKTX

growth of $100 · dividends reinvested · last 6y
CMPX -88.7% (-30.5%/yr)NKTX -92.5% (-35.0%/yr)CMPX compounded faster over this window
050100Start $10020222023202420252026$11$8
CMPX NKTX

CMPX vs NKTX: by the numbers

  • •CMPX is the larger company ($177M vs $172M market cap).

Metrics side by side

Valuation

MetricCMPXNKTX
P/B ratio1.070.69

Profitability

MetricCMPXNKTX
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-44.23%-47.36%
ROIC-46.59%-42.11%

Growth (annualized)

MetricCMPXNKTX
Total return CAGR (5Y)-22.79%-37.28%

Frequently asked

How have CMPX and NKTX total returns compared?
Over the past 5 years, CMPX delivered -22.79% and NKTX delivered -37.28% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.